Leading global contract research organizations based on revenue 2023

In 2023, the leading contract research organizations worldwide included Laboratory Corporation of America Holdings, Thermo Fisher Scientific, and IQVIA. The first ranked company, Thermo Fisher Scientific, which acquired Pharmaceutical Product Development (PPD) in 2021, generated over 23 billion U.S. dollars in revenue through its clinical research business. Contract research organizations Contract research organizations (CROs) are companies that are contracted by larger pharmaceutical companies to manage select aspects of clinical trials. Today, CROs are essential for pharmaceutical research and development. Pharmaceutical companies are spending more money than ever on research and development, and there is no indication that spending will decrease in the future. Evidence suggests that CROs will become even more valuable. The clinical CRO market is expected to increase to over 100 billion U.S. dollars by the beginning of the next decade. Pharmaceutical research and development Globally, Roche and Johnson & Johnson will be the top pharmaceutical companies based on their projected research and development spending. There are regional differences in research and development among pharmaceutical companies. Of all pharmaceutical companies globally, those based in the U.S. develop the highest number of new chemical or biological entities.

于2023年，全球领先的合同研究机构包括美国实验室公司控股有限公司、赛默飞世尔科学公司和艾昆纬。位列第一的赛默飞世尔科学公司，在2021年收购了制药产品开发公司（PPD），其临床研究业务创造了超过230亿美元的营业收入。合同研究机构（CROs）系由大型制药公司委托以管理临床试验选定方面的企业。今日，CROs对于制药研究与发展至关重要。制药公司在研发上的投入前所未有，且未来投入减少的迹象尚未显现。证据表明，CROs的价值将进一步提升。预计到下一个十年伊始，临床CRO市场将增长至超过1000亿美元的规模。在全球范围内，罗氏公司和强生公司预计将成为研发投入最高的制药公司。制药公司在研发方面的区域差异明显。在全球所有制药公司中，美国公司研发的新化学或生物实体数量最多。